Verastem Oncology announces leadership changes to speed up its next phase of growth: Boston Thursday, December 18, 2025, 18:00 Hrs [IST] Verastem Oncology, a biopharmaceutical com ...
End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 - - Over ...
The coprimary endpoints were the proportion of zasocitinib-treated patients achieving static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) and Psoriasis Area and Severity Index ...
Pelareorep combined with standard chemotherapy achieved a 33% objective response rate in KRAS-mutant MSS mCRC, surpassing ...
A national prospective study has confirmed a long-suspected link between Agent Orange and a rare but serious form of blood ...
Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...
Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback